ISPO

Published in Cancer Detection and Prevention 1993; 17(1).

Clinical usefulness of combined use of two new tumor markers, CA602 and CA54/61, for detection of ovarian cancer

Y Udagawa, MD, K Ito, MD, H Sasaki, MD, S Nozawa, MD

Dept of Obstet. & Gynecol. Keio Univ School of Medicine Tokyo 160, Japan

We recently found two new antigenic tumor markers, CA602 analogous to CA125, and CA54/61, a mucin-type glycoprotein. Preliminary data showed that these two markers were detected in high frequency in sera of ovarian cancer patients. CA602 was somewhat disadvantageous in that its positive rate was rather low in patients with mucinous cystadenocarcinoma and relatively high in those with endometriosis like CA125, whereas CA54/61 had characteristics complemental to those of CA602. In this study, 5299 serum samples were measured for these markers, and differences between their single and combined uses compared. Results: 1) The CA602 positive rate was 2% for healthy females, 40% for endometriosis patients, and 70% for ovarian cancer patients. The CA602 assay system was more sensitive than the CA125 in measuring very low marker levels, indicating that CA602 is superior to CA125 in terms of early detection of recurrent ovarian cancers. 2) The CA54/61 positive rate for the same groups was 7%, 19%, and 61%, respectively. 3) The combination-positive rate (CA602-or CA54/61 positive) was 9%, 43%, and 81%, respectively I and was more than 70% for ovarian cancer patients regardless of histological type of cancer. Thus, the serum level measurement of both CA602 and CA54/61 is effective in the diagnosis of ovarian cancer.

KEY WORDS: Tumor marker, Ovarian cancer.

Paper presented at the International Symposium on Cofactor Interactions and Cancer Prevention; Nice, France; March 17-19, 1993; in the section on Diagnostic Markers.

http://www.cancerprev.org/Journal/Issues/17/1/35/1269